SNCA and Parkinson disease: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, second only to Alzheimer’s disease, and refers to α-synucleinopathies characterized by loss of the dopaminergic and monoaminergic neurons in substantia nigra pars compacta (SNpc) and ventral tegmental area, as well as by the accumulation, aggregation and spread of α-Synuclein (αSyn) within neurons and non-neuronal cells including microglia, pericytes, astrocytes, and oligodendrocytes [1].